Oruka Therapeutics (ORKA) Net Cash Flow (2010 - 2026)

Oruka Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 88.25% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was -$34.2 million, a 161.19% decrease from a year earlier, with the FY2025 full-year figure at -$14.6 million, down 123.78% from the prior year.
• Net Cash Flow improved to $2.6 million in Q1 2026 per ORKA's latest filing, from -$44.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $395.8 million in Q3 2024 and bottomed at -$349.3 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$1.6 million (2023), against an average of $2.0 million.
• Biggest YoY gain for Net Cash Flow was 23812.04% in 2024; the steepest drop was 32977.65% in 2024.
• Year by year, Net Cash Flow stood at -$1.5 million in 2022, then gained by 29.32% to -$1.1 million in 2023, then sank by 32977.65% to -$349.3 million in 2024, then surged by 87.31% to -$44.3 million in 2025, then surged by 105.83% to $2.6 million in 2026.
• Per Business Quant, the three latest ORKA Net Cash Flow figures stand at $2.6 million (Q1 2026), -$44.3 million (Q4 2025), and $25.9 million (Q3 2025).